SEC
SlamSEC
SearchBrowseEarnings

MUSTANG BIO, INC.

Nasdaq:MBIO
Pharmaceutical Preparations·WALTHAM, MA
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

Summary Financials

S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency (X-SCID).

CEO
Litchman Manuel Md
Revenue
$50,000
FY 2019
Adj. EBITDA
-$47.4M
-94800.0% margin
FY 2024
Net Income
-$51.6M
-103204.0% margin
FY 2024
EPS (Diluted)
-$299.95
FY 2024
Stock Price
$0.99
+2.3%
2026-03-11
52W Range
$0.53 – $7.00
P/E Ratio
-0.0x
Market Cap
$24.7M
Cash
$6.2M
FY 2024
Total Debt
$28.7M
FY 2023
Net Debt
$22.5M
FY 2023
Enterprise Value
$47.2M
Debt / EBITDA
-0.5x
FY 2019
EV / EBITDA
-1.0x
Employees
—